Last Updated:
Anthem Biosciences IPO: Investors can check their allotment status on the websites of registrar Kfin Technologies as well as exchanges BSE and NSE.
Anthem Biosciences IPO: Check allotment status, listing date and latest GMP.
Anthem Biosciences IPO Allotment Status And GMP: The basis of allotment of the Anthem Biosciences IPO has been finalised, and investors can check their allotment status on the websites of registrar Kfin Technologies as well as exchanges BSE and NSE. Now, all eyes are on its listing, which is scheduled to take place on both BSE and NSE on Monday, July 21.
The IPO was open for public subscription between July 14 and July 16. It received a strong 67.42 times subscription, garnering bids for 2,81,49,30,794 shares as against the 4,17,50,321 shares on offer. The retail and NII participation stood at 5.98x and 44.70x, respectively. The QIB category received a 192.80x subscription.
Anthem Biosciences IPO: A Step-By-Step Guide To Check Allotment Status
Option 1: Kfin Technologies (Registrar) Website
Kfin Technologies is the registrar for the Anthem Biosciences IPO. Follow these steps to check your allotment status:
Visit the Registrar’s Website: Go to the Kfin Technologies’ portal at https://ipostatus.kfintech.com/.
Select the IPO: From the dropdown menu, choose ‘Anthem Biosciences Limited’. Note that the IPO name will only appear once the allotment is finalised.
Choose an Identification Mode: Select one of the following options to check your status:
- Application Number
- Demat Account Number (DP ID/Client ID)
- PAN ID
Enter Details: Input the details corresponding to the selected mode (e.g., your PAN, application number, or Demat account details).
Complete CAPTCHA: Fill in the CAPTCHA for security verification and click ‘Submit’ to view your allotment status. The status will show whether shares were allotted and, if so, how many.
Option 2: Check Allotment Status on BSE Website
You can also check the allotment status on the BSE website. Here’s how:
Visit the BSE IPO Page: Go to https://www.bseindia.com/investors/appli_check.aspx.
Select Issue Type: Choose “Equity” as the issue type.
Select IPO: From the dropdown menu, select ‘Anthem Biosciences Limited’.
Enter Details: Provide your Application Number or PAN.
Complete CAPTCHA: Tick the “I’m not a robot” CAPTCHA and click “Search” to view your allotment status.
Anthem Biosciences IPO GMP Today
The IPO’s grey market premium currently stands at 25.26%, indicating strong listing gains.
According to market observers, unlisted shares of Anthem Biosciences Ltd are currently trading at Rs 714 against its upper IPO price of Rs 570. It means a grey market premium or GMP of Rs 144, which is 25.26% over its issue price, indicating strong listing.
The GMP is based on market sentiments and keeps changing. ‘Grey market premium’ indicates investors’ readiness to pay more than the issue price.
The price band of the mainboard IPO, which aims to raise Rs 3,395 crore, was fixed in the range of Rs 540 to Rs 570.
Anthem Biosciences IPO: More Info
The IPO is entirely an offer-for-sale (OFS). So, the company will not receive any funds from the issue and the proceeds will go to the selling shareholders.
Anthem Biosciences raised Rs 1,016 crore from anchor investors ahead of its initial share-sale opening for public subscription. Some of the investors that participated in the anchor book are — Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds and Societe Generale, HDFC MF (MF), ICICI Prudential MF, Axis MF, UTI MF, Quant MF and Motilal Oswal MF.
Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing.
It also manufactures and sells complex specialized fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars.
Sai Life Sciences Ltd, Syngene International, Suven Life Sciences and Divi’s Laboratories are the listed peers of Anthem Biosciences.
JM Financial, Citigroup Global Markets India, J P Morgan India and Nomura Financial Advisory and Securities (India) are the book-running lead managers for the issue.
Haris is Deputy News Editor (Business) at news18.com. He writes on various issues related to personal finance, markets, economy and companies. Having over a decade of experience in financial journalism, Haris h…Read More
Haris is Deputy News Editor (Business) at news18.com. He writes on various issues related to personal finance, markets, economy and companies. Having over a decade of experience in financial journalism, Haris h… Read More
view comments
- First Published:
